{
  "ticker": "ADR",
  "pdf_display_url": "https://www.asx.com.au/asx/v2/statistics/displayAnnouncement.do?display=pdf&idsId=02961447",
  "id": "02961447",
  "pages": 48,
  "price_sensitive": true,
  "date": "20250624",
  "time": "1114",
  "pdf_url": "https://announcements.asx.com.au/asxpdf/20250624/pdf/06l1nc49j3m5k9.pdf",
  "summary": "### **Material Information Summary \u2013 ASX Capital Raising Announcement**  \n\n#### **1. Offer Structure**  \n- **Type**: Accelerated Non-renounceable Entitlement Offer  \n  - **Components**:  \n    - **New Shares**: 1 for 1 pro-rata at A$0.005 per share.  \n    - **New Options**: 1 option per New Share (exercise price A$0.005, expiry 31 July 2026).  \n    - **Bonus Options**: 1 additional option per New Option exercised before 15 November 2025 (expiry 15 November 2026).  \n  - **Top-Up Facility**: Eligible shareholders may apply for additional shares beyond entitlement (subject to availability).  \n  - **Partial Underwriting**: A$1 million underwritten by PAC Partners Securities Pty Ltd (6% fee).  \n  - **Sub-underwriters**: Trudell Medical Limited and Phillip Asset Management Ltd (A$500k each).  \n\n#### **2. Key Dates**  \n- **Record Date**: 26 June 2025 (7:00 pm AEST).  \n- **Retail Offer Period**: 1 July \u2013 10 July 2025 (closing 5:00 pm AEST).  \n- **Issue Dates**:  \n  - Institutional: 27 June 2025.  \n  - Retail: 17 July 2025.  \n\n#### **3. Capital Raised & Dilution**  \n- **Maximum Funds Raised**: ~A$4 million (before costs).  \n- **New Shares Issued**: Up to 800 million (post-issue total: ~1.7 billion shares).  \n- **Options Issued**: Up to 800 million New Options + 800 million potential Bonus Options.  \n- **Dilution Impact**: Non-participating shareholders face significant dilution (Issue Price: 29\u201337% discount to recent prices).  \n\n#### **4. Use of Proceeds** (A$4 million)  \n- Customer onboarding & scale-up (A$0.8M)  \n- Product development (A$0.3M)  \n- Sales/data science (A$1.0M)  \n- Working capital (A$1.3M)  \n- Offer costs (A$0.4M)  \n\n#### **5. Key Risks**  \n- **Capital Structure**: Post-offer, convertible notes (A$0.9M pending approval) and stock appreciation rights remain outstanding.  \n- **Market Price**: A$0.005/share represents a 29\u201337% discount to recent trading (VWAP: A$0.0079).  \n- **Liquidity Impact**: High issuance volume may pressure share price.  \n\n#### **6. Additional Notes**  \n- **No ASX Listing for Options**: New Options/Bonus Options are unlisted.  \n- **No Cooling-Off Rights**: Applications are binding.  \n\n**Priority**: Focuses on structural terms, dilution, and timeline\u2014critical for trading and capital allocation decisions. Excludes non-material operational/legal details.  \n\n*Summary tailored for ECM analysis\u2014concise and actionable.*",
  "usage": {
    "prompt_tokens": 31998,
    "completion_tokens": 651,
    "total_tokens": 32649,
    "prompt_tokens_details": null
  },
  "model": "deepseek/deepseek-chat-v3-0324:free",
  "processed_at": "2025-06-24T01:40:34.381107"
}